Literature DB >> 19004960

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Andreas Mörner1, Iyadh Douagi, Mattias N E Forsell, Christopher Sundling, Pia Dosenovic, Sijy O'Dell, Barna Dey, Peter D Kwong, Gerald Voss, Rigmor Thorstensson, John R Mascola, Richard T Wyatt, Gunilla B Karlsson Hedestam.   

Abstract

Currently there is limited information about the quality of immune responses elicited by candidate human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env)-based immunogens in primates. Here we describe a comprehensive analysis of neutralizing antibody and T-cell responses obtained in cynomolgus macaques by three selected immunization regimens. We used the previously described YU2-based gp140 protein trimers administered in an adjuvant, preceded by two distinct priming strategies: either alphavirus replicon particles expressing matched gp140 trimers or gp120 core proteins stabilized in the CD4-bound conformation. The rationale for priming with replicon particles was to evaluate the impact of the expression platform on trimer immunogenicity. The stable core proteins were chosen in an attempt to expand selectively lymphocytes recognizing common determinants between the core and trimers to broaden the immune response. The results presented here demonstrate that the platform by which Env trimers were delivered in the priming (either protein or replicon vector) had little impact on the overall immune response. In contrast, priming with stable core proteins followed by a trimer boost strikingly focused the T-cell response on the core sequences of HIV-1 Env. The specificity of the T-cell response was distinctly different from that of the responses obtained in animals immunized with trimers alone and was shown to be mediated by CD4(+) T cells. However, this regimen showed limited or no improvement in the neutralizing antibody responses, suggesting that further immunogen design efforts are required to successfully focus the B-cell response on conserved neutralizing determinants of HIV-1 Env.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004960      PMCID: PMC2612354          DOI: 10.1128/JVI.01102-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.

Authors:  Maria Sundbäck; Iyadh Douagi; Cecilia Dayaraj; Mattias N E Forsell; Eva K L Nordström; Gerald M McInerney; Karin Spångberg; Linda Tjäder; Eivor Bonin; Magnus Sundström; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  Virology       Date:  2005-08-10       Impact factor: 3.616

Review 3.  Alphavirus vectors for gene expression and vaccines.

Authors:  S Schlesinger; T W Dubensky
Journal:  Curr Opin Biotechnol       Date:  1999-10       Impact factor: 9.740

4.  Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.

Authors:  Eva K L Nordström; Mattias N E Forsell; Christina Barnfield; Eivor Bonin; Tomas Hanke; Magnus Sundström; Gunilla B Karlsson; Peter Liljeström
Journal:  J Gen Virol       Date:  2005-02       Impact factor: 3.891

5.  Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

Authors:  Mikyung Kim; Zhi-Song Qiao; David C Montefiori; Barton F Haynes; Ellis L Reinherz; Hua-Xin Liao
Journal:  AIDS Res Hum Retroviruses       Date:  2005-01       Impact factor: 2.205

6.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88.

Authors:  Asa S Hidmark; Gerald M McInerney; Eva K L Nordström; Iyadh Douagi; Kristen M Werner; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.

Authors:  P Berglund; M N Fleeton; C Smerdou; P Liljeström
Journal:  Vaccine       Date:  1999-02-05       Impact factor: 3.641

9.  An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Authors:  Silvia Perri; Catherine E Greer; Kent Thudium; Barbara Doe; Harold Legg; Hong Liu; Raul E Romero; Zequn Tang; Qian Bin; Thomas W Dubensky; Michael Vajdy; Gillis R Otten; John M Polo
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more
  41 in total

1.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.

Authors:  Barbara J Flynn; Kathrin Kastenmüller; Ulrike Wille-Reece; Georgia D Tomaras; Munir Alam; Ross W Lindsay; Andres M Salazar; Beatriz Perdiguero; Carmen E Gomez; Ralf Wagner; Mariano Esteban; Chae G Park; Christine Trumpfheller; Tibor Keler; Giuseppe Pantaleo; Ralph M Steinman; Robert Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-05       Impact factor: 11.205

Review 4.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Authors:  Ivelin S Georgiev; M Gordon Joyce; Tongqing Zhou; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

5.  Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Authors:  Paola Martinez-Murillo; Karen Tran; Javier Guenaga; Gustaf Lindgren; Monika Àdori; Yu Feng; Ganesh E Phad; Néstor Vázquez Bernat; Shridhar Bale; Jidnyasa Ingale; Viktoriya Dubrovskaya; Sijy O'Dell; Lotta Pramanik; Mats Spångberg; Martin Corcoran; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

6.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

7.  Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.

Authors:  Iyadh Douagi; Mattias N E Forsell; Christopher Sundling; Sijy O'Dell; Yu Feng; Pia Dosenovic; Yuxing Li; Robert Seder; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

8.  Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.

Authors:  Ronald Willey; Martha C Nason; Yoshiaki Nishimura; Dean A Follmann; Malcolm A Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

9.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

10.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.